sickle cell disease

Sickle cell community scrambles to find safe plan after a drug is pulled from the market
Stat
Mon, 09/30/24 - 09:56 am
Pfizer
sickle cell disease
Oxbryta
patients
Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta
Fierce Pharma
Wed, 09/25/24 - 10:29 pm
Pfizer
sickle cell disease
Oxbryta
Bluebird stock plummets 18% with slow uptake of sickle cell disease gene therapy Lyfgenia
Fierce Pharma
Wed, 08/14/24 - 10:31 pm
Bluebird Bio
sickle cell disease
Vertex Pharmaceuticals
Lyfgenia
Casgevy
Vertex presents longer-term data that shows durability and consistency of Casgevy
Fierce Pharma
Fri, 06/14/24 - 11:30 am
Vertex Pharmaceuticals
sickle cell disease
FDA
Casgevy
First Patient Begins Newly Approved Sickle Cell Gene Therapy
NY Times, NY
Mon, 05/6/24 - 11:40 am
Bluebird Bio
gene therapy
sickle cell disease
patients
Lyfgenia
Pfizer Terminates Phase III Sickle Cell Study Due to Slow Patient Recruitment
BioSpace
Wed, 03/27/24 - 10:58 am
Pfizer
sickle cell disease
inclacumab
clinical trials
Bluebird Extends Cash Runway with $175M Financing to Support Gene Therapy Launch
BioSpace
Tue, 03/19/24 - 11:22 am
Bluebird Bio
funding
sickle cell disease
Lyfgenia
Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value
BioSpace
Thu, 03/14/24 - 06:19 pm
Vertex Pharmaceuticals
UK
sickle cell disease
CRISPR
Casgevy
Bluebird bio inks first Medicaid coverage agreement for sickle cell gene therapy, signing on with Michigan
Fierce Pharma
Mon, 03/11/24 - 11:33 am
Bluebird Bio
Michigan
lovo-cel
Lyfgenia
Medicaid
sickle cell disease
gene therapy
Sickle Cell Gene Therapies Seen as Cost Effective Below $2M Threshold: Study
BioSpace
Tue, 01/23/24 - 11:18 am
gene therapy
sickle cell disease
drug pricing
Vertex Pharmaceuticals
Bluebird Bio
Bluebird bio's Lyfgenia launch progresses with 2nd major outcomes-based coverage deal
Fierce Pharma
Thu, 01/4/24 - 11:37 am
Bluebird Bio
Lyfgenia
sickle cell disease
gene therapy
Bluebird’s Newly Approved SCD Gene Therapy Faces Rough Road with Hefty Price Tag, Boxed Warning
BioSpace
Mon, 12/11/23 - 11:20 am
Bluebird Bio
sickle cell disease
Lyfgenia
gene therapy
CRISPR
FDA approves bluebird's sickle cell disease gene therapy. Can Lyfgenia overcome CRISPR's halo?
Fierce Pharma
Sun, 12/10/23 - 11:15 pm
Bluebird Bio
sickle cell disease
FDA
CRISPR
Lyfgenia
ASH: Pfizer, swimming in crowded waters, eyes wide impact for sickle cell, hemophilia assets
Fierce Biotech
Sun, 12/10/23 - 11:12 pm
Pfizer
sickle cell disease
ASH
marstacimab
In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease
Stat
Fri, 12/8/23 - 11:36 am
Vertex Pharmaceuticals
FDA
CRISPR
gene editing
Casgevy
sickle cell disease
FDA Could Approve First CRISPR Treatment Today That Might Cure Sickle Cell
Forbes
Fri, 12/8/23 - 09:54 am
Vertex Pharmaceuticals
Casgevy
FDA
CRISPR
sickle cell disease
Where Will Vertex Pharmaceuticals Be in 10 Years?
Motley Fool
Mon, 12/4/23 - 09:31 am
Vertex Pharmaceuticals
cystic fibrosis
exa-cel
sickle cell disease
Cell & Gene Therapy Space Gears Up for First CRISPR Approval
BioSpace
Mon, 11/13/23 - 11:48 am
CRISPR
gene therapy
cell therapy
sickle cell disease
exa-cel
Vertex Pharmaceuticals
CRISPR Therapeutics
AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug
Fierce Biotech
Thu, 11/9/23 - 09:58 am
AstraZeneca
obesity
sickle cell disease
Eccogene
earnings
Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says
Fierce Pharma
Tue, 11/7/23 - 11:02 pm
Bluebird Bio
Vertex Pharmaceuticals
exa-cel
lovo-cel
sickle cell disease
drug pricing

Pages